Two of AstraZeneca’s Best-Sellers Show Advances in Deadly Ailments
An AstraZeneca logo sits on the foil of a blister pack.
Photographer: Simon Dawson/Bloomberg
This article is for subscribers only.
Two of AstraZeneca Plc’s best-selling medicines showed advances in lethal diseases.
Imfinzi, a cancer drug, won approval from the U.S. Food and Drug Administration to treat extensive-stage small cell lung cancer, one of the most deadly forms of lung cancer.